1 Erratum to: Drugs (2015) 75:75–82 DOI 10.1007/s40265-014-0329-y

The author has alerted us to the following errors:

Page 79, column 2, paragraph 1, line 7.

The sentence that previously read:

‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four with prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’

should read:

‘A more recent review of this patient group (median follow-up 141 days) reported that 13 patients, four without prior brain irradiation, continued on study treatment without progression (reported in an abstract) [23].’

Page 80, figure 4 legend, lines 5 and 6.

The figure legend that previously read:

‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in ≥10 % of patients (n = 46) in the phase 2 portion of a phase 1–2 study [18]. ALP alanine phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CPK creatinine phosphokinase.’

should read:

‘Treatment-related adverse events associated with twice-daily alectinib 300 mg in patients with ALK-rearranged advanced non-small cell lung cancer. Adverse events reported in ≥10 % of patients (n = 46) in the phase 2 portion of a phase 1–2 study [18]. ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CPK creatine phosphokinase.’